NCT06786780 2025-03-26ECCOChongqing University Cancer HospitalPhase 2 Enrolling by invitation50 enrolled
NCT06755515 2025-01-01A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical CancerShandong New Time Pharmaceutical Co., LTDPhase 2/3 Enrolling by invitation510 enrolled